A Phase 2 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 134 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-05.
Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 6 in phase 2, and was the 1st registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
Sir Run Run Shaw Hospital
Ages 18–100
By country, each count listing its studies:
etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2015.
This study's enrollment of 156 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 195 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Arena Pharmaceuticals, one of the names counted as Pfizer. Under that name alone:
Arena Pharmaceuticals is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2015, is one of 12 in phase 2, and was the 10th registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
1 of the studies testing etrasimod in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07782242Sir Run Run Shaw HospitalComaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral, low dose, daily for 12 Weeks
Drug: Etrasimod
Oral, high dose, daily for 12 weeks
Drug: Etrasimod
Oral, placebo, daily for 12 weeks.
Drug: Placebo
Also known as: APD334
Change From Baseline in Adapted Mayo Score (MCS) at Week 12
The adapted MCS was used to measure disease activity of ulcerative colitis. It consisted of 3 subscores (stool frequency, rectal bleeding, and findings of endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The adapted MCS was calculated as the sum of the 3 subscores, and the overall score values ranged from 0 to 9, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.
Time frame: Baseline and Week 12
Percentage of Participants Who Achieved Endoscopic Improvement at Week 12
For determination of the endoscopic subscore of the MCS, a flexible proctosigmoidoscopy, performed with a videoendoscope following a cleansing prep (oral or rectal cathartic) was performed at screening (within 10 days prior to administration of the first dose of study drug) and the Week 12 visit. This efficacy procedure assessed endoscopic mucosal appearance. The results were rated on a scale from 0 to 3, indicating normal to severe. Endoscopic improvement was defined as Mayo endoscopic subscore (using findings of flexible proctosigmoidoscopy) of ≤1 point. Multiple imputation method was used to handle missing data.
Time frame: Week 12
Change From Baseline in 2-component MCS at Week 12
The 2-component MCS was used to measure disease activity of ulcerative colitis. It consisted of 2 subscores (rectal bleeding and findings on endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The 2-component MCS was calculated as the sum of the 2 subscores, and the overall score value ranged from 0 to 6, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.
Time frame: Baseline and Week 12
Change From Baseline in Total Mayo Score (TMS) at Week 12
The TMS was used to measure disease activity of ulcerative colitis. It consisted of 4 subscores \[stool frequency, rectal bleeding, findings of endoscopy (flexible proctosigmoidoscopy), and Physician's Global Assessment (PGA) score\], each of which was rated on a scale from 0 to 3, indicating normal to severe. The TMS was calculated as the sum of the 4 subscores, and the overall score values ranged from 0 to 12, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.
Time frame: Baseline and Week 12
Trichotomous Composite Score of Clinical Remission and Clinical Response at Week 12
The trichotomous composite score of clinical remission and clinical response at Week 12 is an ordinal categorical endpoint with 3 categories (score ranging 0 to 2: score 2 for achieving both clinical remission and clinical response; 1 for only achieving clinical response, and 0 for achieving neither). Multiple imputation method was used to handle missing data.
Time frame: Week 12
Percentage of Participants Who Achieved Clinical Remission at Week 12
A participant was considered to have achieved clinical remission if he/she had: 1) an endoscopy score using flexible proctosigmoidoscopy of 0 or 1 (excluding friability), 2) a rectal bleeding score of 0 or 1, and 3) a stool frequency score of 0 or 1 with a decrease of ≥1 point from baseline. Multiple imputation method was used to handle missing data.
Time frame: Week 12
Percentage of Participants Who Achieved Clinical Response at Week 12
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission defined above, or met criteria of clinical response. Clinical response was defined as a decrease in the adapted MCS of ≥ 2 points and a decrease of ≥ 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1.
Time frame: Week 12
The study included a screening period (up to 28 days), a double-blind induction treatment period (12 weeks), and a possible follow-up visit (2 weeks after the last study visit). The target population consisted of male or female participants aged between 18 and 80 years (inclusive), with moderately to severely active Ulcerative Colitis.
| Milestone | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Started | 52 | 50 | 54 |
| Completed | 47 | 46 | 48 |
| Not completed | 5 | 4 | 6 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Adverse event | 4 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 5 |
| Withdrew: Sponsor decision | 0 | 0 | 1 |
The adapted MCS was used to measure disease activity of ulcerative colitis. It consisted of 3 subscores (stool frequency, rectal bleeding, and findings of endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The adapted MCS was calculated as the sum of the 3 subscores, and the overall score values ranged from 0 to 9, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.
| score on a scale | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Adapted Mayo Score (MCS) at Week 12 | -1.94 (-2.45 to -1.42) | -2.49 (-3.01 to -1.98) | -1.50 (-2.00 to -1.01) |
For determination of the endoscopic subscore of the MCS, a flexible proctosigmoidoscopy, performed with a videoendoscope following a cleansing prep (oral or rectal cathartic) was performed at screening (within 10 days prior to administration of the first dose of study drug) and the Week 12 visit. This efficacy procedure assessed endoscopic mucosal appearance. The results were rated on a scale from 0 to 3, indicating normal to severe. Endoscopic improvement was defined as Mayo endoscopic subscore (using findings of flexible proctosigmoidoscopy) of ≤1 point. Multiple imputation method was used to handle missing data.
| percentage of participants | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Endoscopic Improvement at Week 12 | 22.5 | 41.8 | 17.8 |
The 2-component MCS was used to measure disease activity of ulcerative colitis. It consisted of 2 subscores (rectal bleeding and findings on endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The 2-component MCS was calculated as the sum of the 2 subscores, and the overall score value ranged from 0 to 6, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.
| score on a scale | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 2-component MCS at Week 12 | -1.30 (-1.66 to -0.95) | -1.75 (-2.11 to -1.40) | -0.92 (-1.26 to -0.57) |
The TMS was used to measure disease activity of ulcerative colitis. It consisted of 4 subscores \[stool frequency, rectal bleeding, findings of endoscopy (flexible proctosigmoidoscopy), and Physician's Global Assessment (PGA) score\], each of which was rated on a scale from 0 to 3, indicating normal to severe. The TMS was calculated as the sum of the 4 subscores, and the overall score values ranged from 0 to 12, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.
| score on a scale | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Total Mayo Score (TMS) at Week 12 | -2.69 (-3.36 to -2.02) | -3.35 (-4.03 to -2.68) | -2.08 (-2.73 to -1.44) |
The trichotomous composite score of clinical remission and clinical response at Week 12 is an ordinal categorical endpoint with 3 categories (score ranging 0 to 2: score 2 for achieving both clinical remission and clinical response; 1 for only achieving clinical response, and 0 for achieving neither). Multiple imputation method was used to handle missing data.
| score on a scale | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Trichotomous Composite Score of Clinical Remission and Clinical Response at Week 12 | 0.60 ± 0.11 | 0.84 ± 0.13 | 0.41 ± 0.09 |
A participant was considered to have achieved clinical remission if he/she had: 1) an endoscopy score using flexible proctosigmoidoscopy of 0 or 1 (excluding friability), 2) a rectal bleeding score of 0 or 1, and 3) a stool frequency score of 0 or 1 with a decrease of ≥1 point from baseline. Multiple imputation method was used to handle missing data.
| percentage of participants | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 12 | 16.0 | 33.0 | 8.1 |
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission defined above, or met criteria of clinical response. Clinical response was defined as a decrease in the adapted MCS of ≥ 2 points and a decrease of ≥ 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1.
| percentage of participants | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Response at Week 12 | 43.7 | 50.6 | 32.5 |
Collected over Up to approximately 16 weeks i.e. from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etrasimod 1 mg | 0/52 (0%) | 3/52 (5.8%) | 11/52 (21.2%) |
| Etrasimod 2 mg | 0/50 (0%) | 0/50 (0%) | 11/50 (22%) |
| Placebo | 0/54 (0%) | 6/54 (11.1%) | 9/54 (16.7%) |
| Event | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 2/52 | 0/50 | 3/54 |
| Anal abscessInfections and infestations | 1/52 | 0/50 | 0/54 |
| Abdominal painGastrointestinal disorders | 0/52 | 0/50 | 1/54 |
| Duodenal ulcer perforationGastrointestinal disorders | 0/52 | 0/50 | 1/54 |
| JaundiceHepatobiliary disorders | 0/52 | 0/50 | 1/54 |
| HydronephrosisRenal and urinary disorders | 0/52 | 0/50 | 1/54 |
| Event | Etrasimod 1 mg | Etrasimod 2 mg | Placebo |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/52 | 2/50 | 2/54 |
| NasopharyngitisInfections and infestations | 2/52 | 1/50 | 4/54 |
| HeadacheNervous system disorders | 0/52 | 3/50 | 1/54 |
| AnaemiaBlood and lymphatic system disorders | 2/52 | 3/50 | 2/54 |
| Colitis ulcerativeGastrointestinal disorders | 3/52 | 2/50 | 1/54 |
The analysis was performed using the safety population that consisted of all randomized participants who received at least 1 dose of the study drug.
| Age, Continuous(years) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| Median | 44.0 (21 to 64) | 38.5 (21 to 67) | 46.0 (20 to 73) | 42 (20 to 73) |
| Age, Customized(Subjects) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| Adults (18-64 years) | 52 | 49 | 49 | 150 |
| From 65-80 years | 0 | 1 | 5 | 6 |
| Sex: Female, Male(Participants) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 22 | 23 | 22 | 67 |
| Male | 30 | 27 | 32 | 89 |
| Ethnicity (NIH/OMB)(Participants) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 3 | 7 |
| Not Hispanic or Latino | 49 | 49 | 51 | 149 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 2 | 1 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 47 | 49 | 51 | 147 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Adapted Mayo Score (MCS)(score on a scale) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 6.5 ± 1.23 | 6.6 ± 1.17 | 6.5 ± 1.51 | 6.5 ± 1.31 |
| The 2-component MCS(score on a scale) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 4.2 ± 0.75 | 4.2 ± 0.75 | 4.2 ± 0.91 | 4.2 ± 0.80 |
| Total Mayo Score (TMS)(score on a scale) | Etrasimod 1 mg | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.8 ± 1.43 | 8.9 ± 1.47 | 8.7 ± 1.72 | 8.8 ± 1.54 |
Showing the first 100 of 134 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2015 to primary completion in Feb 2018, 27 months.
Results were first posted in Apr 2021, 3 years 1 month after primary completion. A results delay was requested in Feb 2019.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 27 months is close to that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod